HOME >> BIOLOGY >> NEWS
Americans prefer to leave child's sex to chance, survey finds

Most people would not choose the sex of their child if given the option, according to a new nationwide survey. The study is the first to examine the demand and preferences for sex selection among the U.S. general population.

"We found that only 8 percent of people would use pre-implantation sex selection for non-medical reasons," said Dr. Tarun Jain, assistant professor of reproductive endocrinology and infertility at University of Illinois at Chicago and senior author of the report.

The findings, published in the February issue of the journal Fertility and Sterility, are the result of a cross-sectional, web-based survey of 1,197 people (587 men and 610 women) between 18 and 45 years old.

In the study, 77 percent of people who wanted more than one child indicated they either preferred an equal number of boys and girls or had no preference as to the sex of their children.

Pre-conception sex selection using sperm-separation technology is currently available in the United States as part of an FDA-approved clinical trial. The technique is not without controversy, but is expected to become more readily available to consumers at the completion of that trial.

The marketing and increased availability of the technology poses moral, legal and social issues. Some fear that sex selection may disrupt the natural sex ratio, contribute to gender stereotyping and discrimination, and hasten a trend toward "designer babies."

"So far, all of the ethical discussions about sex selection have focused on 'what if' scenarios without any legitimate data," Jain said. "This study should provide a legitimate framework to better lead the discussion about the realistic implications of sex selection technology."

Sperm separation requires patients to provide a sperm sample and undergo an average of three to five cycles of intrauterine insemination at a fertility center, at a cost of approximately $2,500 per attempt.

The survey found t
'"/>

Contact: Sherri McGinnis Gonzalez
smcginn@uic.edu
312-996-8277
University of Illinois at Chicago
13-Feb-2006


Page: 1 2

Related biology news :

1. New clue why MS affects African-Americans differently than Caucasians
2. Slow wave activity during sleep is lower in African-Americans than Caucasians
3. Economic impact of hunger affects all Americans
4. African-Americans at increased risk for earlier preterm births
5. Pills or papayas? Survey finds Americans want healthful foods, not more medicines
6. New diabetes research: Half of Americans have gene that affects how body burns sugar
7. Americans support for embryonic stem cell research declines, VCU Life Sciences survey shows
8. African-Americans with prostate cancer more likely to have family history of prostate, breast cancer
9. MIT survey: Climate change tops Americans environmental concerns
10. Americans less likely to accept evolution than Europeans
11. Americans support free access to research

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Americans prefer leave child sex chance survey finds

(Date:4/14/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that its Wocket® ... York Design Awards under the category  ,Product Design – ... Awards are part of a global multi-disciplinary awards program. ... the marketplace, industry and judging panel. Winners will be ...
(Date:4/8/2015)... April 8, 2015  Infinisource, a leading provider ... and Morpho, a leading supplier of biometric identification ... the market,s most advanced biometrically-enabled time clock, the ... time clock is setting a bold, new standard ... for the small and mid-size employer. When connected ...
(Date:4/2/2015)... GOTHENBURG, Sweden , April 2, 2015 ... for its touch fingerprint sensor FPC1025 from the distributor ... Deliveries will commence during Q2 2015 although the major ... 2015. The sensors will be used by smartphone manufacturers ... of 110 MSEK is included in the communicated revenue ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2
(Date:4/16/2015)... MENLO PARK, Calif. , April 16, ... (DelMar and the Company), a biopharmaceutical company focused on ... drug indications, today announced that the Mayo Clinic ... trial site for the ongoing, multicenter Phase I/II study ... the most common and deadly form of human brain ...
(Date:4/16/2015)... Md. , April 16, 2015  Northwest ... a biotechnology company developing non-toxic DCVax® personalized immune ... been included in the Loncar Cancer Immunotherapy Index ... investors better track the immunotherapy field within the ... have selected "the top 25 companies" in the ...
(Date:4/16/2015)... April 16, 2015 Modality Solutions, ... systems for highly regulated industries, is pleased to ... a monthly columnist for Cold Chain IQ - ... ). His column titled, Global Cold Chain Connections, ... for today’s life sciences, pharmaceutical and healthcare supply ...
(Date:4/15/2015)... OXFORD, England , April 16, 2015 /PRNewswire/ ... company developing novel biological drugs to treat cancer ... research and development arm of AstraZeneca, today announced ... Under the terms of the agreement, ... combining MedImmune,s investigational checkpoint inhibitors MEDI4736 (anti-PD-L1) and/or ...
Breaking Biology Technology:DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 2DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 4DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 5NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 2NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 3Modality Solutions Gary Hutchinson Named Columnist for Cold Chain IQ 2Modality Solutions Gary Hutchinson Named Columnist for Cold Chain IQ 3Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 2Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 3Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 4Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 5Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 6
Cached News: